

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)



(10) International Publication Number
WO 2023/004425 A2

(51) International Patent Classification:

A61K 35/14 (2015.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/074062

(22) International Filing Date:

22 July 2022 (22.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/225,281	23 July 2021 (23.07.2021)	US
63/310,526	15 February 2022 (15.02.2022)	US
63/344,931	23 May 2022 (23.05.2022)	US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, Texas 78701 (US).

(72) Inventors: **LIU, Enli**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **REZVANI, Katy**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **BASAR, Rafet**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **LIU, Bin**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US). **MARIN COSTA, David**; c/o U.T.M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030 (US).

(74) Agent: **SISTRUNK, Melissa L.**; Norton Rose Fulbright US LLP, 1301 McKinney, Suite 5100, Houston, Texas 77010 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: CD3-EXPRESSING NATURAL KILLER CELLS WITH ENHANCED FUNCTION FOR ADOPTIVE IMMUNOTHERAPY

(57) Abstract: Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express the T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with bispecific or multi-specific antibodies that are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).

WO 2023/004425 A2